Metoprololtartraat Teva (Metoprolol Tartrate)

Metoprololtartraat Teva is a selective β1‑adrenergic blocker indicated for several cardiovascular conditions.

• Hypertension: reduces systolic and diastolic blood pressure to lower cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain.
• Myocardial infarction: improves survival by reducing cardiac workload after an acute event.
• Heart failure: lowers heart rate and improves ventricular filling, supporting functional capacity.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

• Metoprolol Tartrate selectively antagonizes β1‑adrenergic receptors in cardiac tissue, inhibiting the effects of endogenous catecholamines. This blockade reduces heart rate, myocardial contractility, and conduction velocity, leading to decreased cardiac output and lower arterial pressure. By limiting sympathetic stimulation, the drug also diminishes myocardial oxygen consumption, which contributes to its anti‑anginal and anti‑arrhythmic properties.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Fatigue or tiredness
• Dizziness, especially when standing quickly
• Cold extremities or reduced peripheral circulation
• Gastrointestinal discomfort such as nausea or abdominal pain
• Sleep disturbances, including insomnia or vivid dreams

Serious or Rare Side Effects

• Bradycardia (abnormally low heart rate)
• Severe hypotension (dangerously low blood pressure)
• Acute heart failure exacerbation
• Bronchospasm in patients with reactive airway disease
• Allergic reactions such as rash, pruritus, or angioedema

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Cardiovascular assessment: review history of heart block, severe bradycardia, or decompensated heart failure.
• Respiratory status: avoid in patients with uncontrolled asthma or chronic obstructive pulmonary disease.
• Diabetes monitoring: watch for masking of hypoglycaemic symptoms.
• Concomitant medications: adjust dose when used with other antihypertensives or rate‑controlling agents.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant.
• Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Metoprololtartraat Teva may interact with several drug classes, requiring dose adjustments or close monitoring.

Major Interactions (Avoid)

• Non‑selective beta‑blockers or other cardio‑selective agents: additive bradycardia and hypotension.
• Calcium channel blockers (verapamil, diltiazem): profound AV‑node conduction delay.
• Potent CYP2D6 inhibitors (e.g., quinidine, paroxetine): markedly increased metoprolol plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: risk of electrolyte imbalance and orthostatic hypotension.
• Antidiabetic drugs (insulin, sulfonylureas): enhanced hypoglycaemia.
• NSAIDs: may blunt antihypertensive effect.